Over the last decade, there has been significant developments in nanotechnology, in particular for combined imaging and therapeutic applications (theranostics). The core or shell of nanoemulsions (NEs) can be loaded with various...
International guidelines do not recommend magnetic resonance imaging (MRI) for all breast cancer patients at primary diagnostics. This study aimed to understand which patient or tumor characteristics are associated with the use...
Phyllodes tumors (PT) are rare entity and surgical resection is the cornerstone of treatment. No standard of care exists regarding adjuvant treatment especially radiation therapy (RT).We analyzed all patients with...
Public health organizations release new recommendations as pandemic rages on The CDC and other...
The expression “It shouldn’t have to happen to you to matter to you” has been making the rounds on...
In women with metastatic breast cancer, programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors are given as the primary line of monotherapy. However, in patients with hormone receptor-positive...
Neoadjuvant chemotherapy is routinely assigned to women with early-stage breast cancer, but approximately 25% of them experience a recurrence within 5 years. Combining pembrolizumab, a humanized antibody, with neoadjuvant...
Several studies have been conducted to investigate the association between breastfeeding and ovarian cancer; some show a positive association, and some show no association at all. This study aims to determine the exact...
Transgender people undergo prolonged hormone treatment, which may be associated with an increased risk of breast cancer. This study aims to evaluate the incidence of breast cancer in trans men and women who received...
Three days packed with presentations The American Society of Clinical Oncology is the leading oncology research meeting worldwide, but just like other medical conferences, ASCO 2020 was forced to make many changes to deliver on...
Although research has linked pre-existing intratumoral immune response—characterized by presence of tumor-infiltrating lymphocytes or cytotoxic effector T cells—with improve prognosis in early triple-negative breast cancer...
Despite research suggesting that mutation in ESR1 is an acquired mechanism of resistance to endocrine therapy (ET), the impact of this mutation on therapy response in primary breast cancer remains unclear. To better understand...
